Answers are grounded in this paper and cite their sources.
BACKGROUND: TFE3-rearranged renal cell carcinoma (TFE3-rRCC) is uncommon and encompasses biologically diverse tumors, while evidence to guide systemic treatment remains sparse. We examined clinical outcomes, treatment patterns, and molecular features in a multicenter real-world cohort. METHODS: We reviewed 151 patients with TFE3-rRCC treated at eight centers in China. Treatment analyses included the 59 patients who had metastatic or relapsed disease and sufficiently detailed treatment records. Response was assessed by RECIST version 1.1. Kaplan-Meier methods were used for time-to-event outcomes, and potential confounding was explored with Cox regression. RESULTS: Median first-line progression-free survival (PFS) was 6.1 months among the 59 treated patients. PFS was longer with first-line ICI/TKI therapy than with TKI monotherapy (log-rank p = 0.034). In an exploratory multivariable model, distant lymph-node metastasis was associated with shorter overall survival (HR, 5.22; 95% CI, 1.17-23.40; p = 0.031). In a small subgroup comparison, NONO-TFE3 tumors had a relatively immune-depleted transcriptomic profile and lower disease control with ICI/TKI therapy. CONCLUSIONS: TFE3-rRCC is a heterogeneous disease with poor survival and a variable therapeutic response. ICI/TKI combinations had modest activity; newer approaches are needed.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: